Crossmark

Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial

Crossref DOI link: https://doi.org/10.1186/s12885-025-14331-5

Published Online: 2025-06-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Ying Ying

Lee, Lian Chen

Zeng, Hong

Gu, Yuan

Xu, Chen

Chen, Wei Dong

Shen, Zhen Bin

Shen, Kun Tang

Cui, Yue Hong

Sun, Yi Hong

Liu, Tian Shu

Tang, Zhao Qing

Wang, Xue Fei
Funding

Funding for this research was provided by:

Foundation from Shanghai Municipal Science and Technology Commission (23ZR1410700; 23Y11902100)

Natural Science Foundation of Fujian Province (2023J011692)
License Information

Text and Data Mining valid from 2025-06-01

Version of Record valid from 2025-06-01
More Information

Article History

Received: 5 November 2024

Accepted: 14 May 2025

First Online: 1 June 2025

Declarations

:

: The study protocol has been approved by the lead ethics committee of Zhongshan Hospital, Fudan University (B2024-157R) and registered on ClinicalTrials.gov (NCT06468280, registration date: 05/28/2024). Informed consent will be obtained from all patients or their legal representatives, using a consent form approved by the ethics committee.

: Study results will be published while ensuring patient confidentiality in compliance with the Declaration of Helsinki, Good Clinical Practice guidelines, the Data Protection Act, and local legal and regulatory requirements.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below